Statistik Asas
| LEI | 5493006XTUBSKFU3W106 |
| CIK | 1597313 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ViewRay, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 12, 2024 |
EX-99.1 2 d757679dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez* ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTISA |
|
| February 12, 2024 |
VRAY / ViewRay Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A 1 d757679dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 4 )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) |
|
| February 7, 2024 |
VRAY / ViewRay Inc. / Fosun International Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm243593d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 7, 2023 |
viewrayinc UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. |
|
| September 7, 2023 |
viewraytechnologies UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 25, 2023 |
VRAY / ViewRay Inc. / EBRAHIMI FARHAD FRED - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2 )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) Brad Nelson 191 University Blvd, Suite 246 Denver, Colora |
|
| July 21, 2023 |
Exhibit 99.1 ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets DENVER, CO, July 21, 2023— ViewRay, Inc. (the “Company”) (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”). Nasdaq has determined that due to the Company’s volu |
|
| July 21, 2023 |
VRAY / ViewRay Inc. / Hudson Executive Capital LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* ViewRay, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92672L107 (CUSIP Nu |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 17, 2023 |
Exhibit 10.2 July 15, 2023 Paul Ziegler Paul, We are excited to extend you an offer for the position of President and Chief Executive Officer. The following outlines the terms of our employment offer to you: Position: President and Chief Executive Officer. Reporting To This position will report and be responsible to the Company’s Board of Directors. Start Date July 15, 2023. Compensation: Base Sal |
|
| July 17, 2023 |
Exhibit 10.3 July 15, 2023 Adam Podbelski Adam, We are excited to extend you an offer for the position of SVP, Commercial Operations. The following outlines the terms of our employment offer to you: Position: Senior Vice President, Commercial Operations. Reporting To: This position will report to Paul Ziegler, President and CEO. Start Date: July 15, 2023. Compensation: Base Salary: An annual salar |
|
| July 17, 2023 |
MidCap Financial Services, LLC 7255 Woodmont Avenue, Suite 300 Bethesda, Maryland 20814 www. |
|
| July 17, 2023 |
Exhibit 99.1 ViewRay® Files Voluntary Chapter 11 Petitions Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, CO, July 17, 2023— ViewRay, Inc. (Nasdaq: VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the “Petitions”) under Chapter 11 of Title 11 the U.S. Bankruptcy Cod |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 6, 2023 |
DE:6L9 / ViewRay Inc. / Neuberger Berman Group LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common (Title of Class of Securities) 92672L07 (CUSIP Number) June 30 , 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 22, 2023 |
VRAY / ViewRay Inc. / EBRAHIMI FARHAD FRED - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1 )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) Brad Nelson 191 University Blvd, Suite 246 Denver, Colora |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ViewRay, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-37725 42-1777485 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1099 18th Street, Suite 3000 Denver, CO 80202 (Address of princip |
|
| May 26, 2023 |
VIEWRAY, INC. CONFLICT MINERALS REPORT FOR THE YEAR ENDED DECEMBER 31, 2022 Exhibit 1.01 VIEWRAY, INC. CONFLICT MINERALS REPORT FOR THE YEAR ENDED DECEMBER 31, 2022 This Conflict Minerals Report (“CMR”) for the year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, (the “Rule”). The Rule was adopted by the Securities and Exchange Commission, (the “SEC”), to implement reporting and disclosure requirements related to C |
|
| May 11, 2023 |
General Release of Claims, dated May 10, 2023, by and between ViewRay, Inc. and William P. Burke Exhibit 10.5 GENERAL RELEASE OF CLAIMS This General Release of Claims (“Release”), dated as of May 10, 2023, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and William P. Burke (“Employee”) (collectively, the “Parties”). Unless otherwise defined herein, any capitalized terms used in this Rele |
|
| May 11, 2023 |
Exhibit 10.6 STANDSTILL AGREEMENT This STANDSTILL AGREEMENT (this “Agreement”) is entered into as of May 10, 2023, by and among VIEWRAY, INC. (“Viewray”) and VIEWRAY TECHNOLOGIES, INC. (“Viewray Technologies” and, together with Viewray, collectively, the “Borrowers” and each individually, a “Borrower”), MIDCAP FUNDING IV TRUST, a Delaware statutory trust, as Agent (in such capacity, together with |
|
| May 11, 2023 |
Exhibit 3.4 CONFIDENTIAL SEVERANCE AGREEMENT This Confidential Severance Agreement (“Agreement”), dated as of DATE, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and NAME (“Employee”) (collectively, the “Parties”). Unless otherwise defined herein, any capitalized terms used in this Agreement |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| May 10, 2023 |
ViewRay Announces First Quarter 2023 Results Exhibit 99.1 ViewRay Announces First Quarter 2023 Results DENVER, May 10, 2023 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights •Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 27, 2023 |
EX-99.C Exhibit 99C AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of First Solar, Inc. Executed as a sealed instrument this 5th day of April, 2018. By: *** Name: |
|
| April 27, 2023 |
EX-99.A Exhibit 99A EXHIBIT INDEX Exhibit A - Power of Attorney Exhibit B - Power of Attorney Exhibit C - Agreement regarding filing of joint Schedule 13D POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the person whose signature appears below hereby constitutes and appoints Brad Nelson his true and lawful attorney-in-fact and agent, for him and in his name, place and stead, in any and all capa |
|
| April 27, 2023 |
EX-99.B Exhibit 99B POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the person whose signature appears below hereby constitutes and appoints Brad Nelson her true and lawful attorney-in-fact and agent, for her and in her name, place and stead, in any and all capacities (including, but not limited to, as a general partner of any partnership, a member or manager of any limited liability company, a |
|
| April 27, 2023 |
VRAY / ViewRay Inc. / EBRAHIMI FARHAD FRED - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) Brad Nelson 191 University Blvd, Suite 246 Denver, Colorado 8 |
|
| April 13, 2023 |
Exhibit 99.1 ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value DENVER, April 13, 2023 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The preliminary results |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 28, 2023 |
Exhibit 21 Subsidiaries Entity Jurisdiction of Organization ViewRay Technologies, Inc. (formerly known as ViewRay Incorporated) Delaware ViewRay GmbH Germany |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-377 |
|
| February 28, 2023 |
General Release of Claims, dated January 6, 2023, by and between ViewRay, Inc. and Zachary Stassen. Exhibit 10.31 GENERAL RELEASE OF CLAIMS This General Release of Claims (“Release”), dated as of January 6, 2023, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and Zachary Stassen (“Employee”) (collectively, the “Parties”). Unless otherwise defined herein, any capitalized terms used in this R |
|
| February 28, 2023 |
Exhibit 10.23 CREDIT, SECURITY AND GUARANTY AGREEMENT dated as of November 14, 2022 by and among VIEWRAY TECHNOLOGIES, INC., VIEWRAY, INC., each as Borrower and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and any guarantor that hereafter becomes party hereto, each as Guarantor, and collectively as Guarantors, and MIDCAP FUNDING IV T |
|
| February 28, 2023 |
Offer Letter to William Burke dated January 6, 2023. Exhibit 10.32 January 6, 2023 William Burke 8 Forster Dr. Norton, MA 02766 William, Congratulations! We are excited to extend you an offer of employment with ViewRay Technologies, Inc. The details of your offer are as follows: Position: EVP, Chief Financial Officer, reporting to Scott Drake, CEO. This is a regular full-time position. Start Date: January 6, 2023 Compensation: Your starting salary w |
|
| February 28, 2023 |
Exhibit 10.29 Amendment No. 2 Amendment Date: February 27, 2023 Parties: ViewRay, Inc. Scott Drake Original Agreement: Employment Agreement dated July 22, 2018, as previously amended December 20, 2018 The below signatories are parties to the Original Agreement. The parties hereby agree to amend the Original Agreement as follows: 1. Section 6.2 of the Original Agreement is hereby stricken and repla |
|
| February 27, 2023 |
a2023-2x27q422earningsap Earnings Call – FY 2022 February 27, 2023 Exhibit 99.2 2©2023 ViewRay Technologies, Inc. All rights reserved. Forward-looking statement This appendix contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this appendix that are not purely historical are forward-looking statements. Such forward-lo |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2023 |
ViewRay Announces Fourth Quarter and Full Year 2022 Results Exhibit 99.1 ViewRay Announces Fourth Quarter and Full Year 2022 Results DENVER, February 27, 2023 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights •Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approxima |
|
| February 10, 2023 |
VRAY / Viewray Inc / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A 1 d441170dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) |
|
| February 10, 2023 |
VRAY / Viewray Inc / Neuberger Berman Group LLC - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* VIEWRAY INC (Name of Issuer) Common (Title of Class of Securities) 92672L07 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 9, 2023 |
VRAY / Viewray Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv02193-viewrayinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: ViewRay Inc. Title of Class of Securities: Common Stock CUSIP Number: 92672L107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 3, 2023 |
VRAY / Viewray Inc / Fosun International Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm233780d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the |
|
| January 25, 2023 |
VRAY / Viewray Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 VRAYSC13GA2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) VIEWRAY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92672L107 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate bo |
|
| January 20, 2023 |
Exhibit 10.1 EXECUTION VERSION COOPERATION AGREEMENT January 20, 2023 Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, New York 10281 Ladies and Gentlemen: ViewRay, Inc. (the “Company”) and Hudson Executive Capital LP, on behalf of itself, its affiliates and its affiliated funds (such affiliates and affiliated funds (which, for the avoidance of doubt, |
|
| January 20, 2023 |
EX-4 2 tm233970d1ex4.htm EXHIBIT 4 Exhibit 4 COOPERATION AGREEMENT January 20, 2023 Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, New York 10281 Ladies and Gentlemen: ViewRay, Inc. (the “Company”) and Hudson Executive Capital LP, on behalf of itself, its affiliates and its affiliated funds (such affiliates and affiliated funds (which, for the avoida |
|
| January 20, 2023 |
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital Exhibit 99.1 ViewRay Enters into Cooperation Agreement with Hudson Executive Capital CLEVELAND, January 20, 2023- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP (“HEC”) to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors (the “Board”), effective as of January 20 |
|
| January 20, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 20, 2023 |
VRAY / Viewray Inc / Hudson Executive Capital LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* ViewRay, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92672L107 (CUSIP Nu |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 9, 2023 |
Exhibit 99.1 ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. “Bill” Burke as Chief Financial Officer DENVER, January 9, 2023 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to cha |
|
| November 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 17, 2022 |
INVESTOR DAY ViewRay NOV. 17 20 22 Exhibit 99.1 ViewRay NOV. 17 20 22 INVESTOR DAY ViewRay NOV. 17 20 22 ?2022 ViewRay Technologies, Inc. All rights reserved. 4 Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-l |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 14, 2022 |
Execution Version i MidCap / Viewray / Credit, Security and Guaranty Agreement Exhibit 10. |
|
| November 14, 2022 |
Exhibit 99.1 ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility Facility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million DENVER, November 14, 2022 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced that it has entered into a new five-year loan facility agreement with MidCap Financial and Silicon Valley Bank |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| November 1, 2022 |
Earnings Call ? Q3 2022 November 1, 2022 Exhibit 99.2 2?2022 ViewRay Technologies, Inc. All rights reserved. Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements i |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 1, 2022 |
ViewRay Announces Third Quarter 2022 Results Exhibit 99.1 ViewRay Announces Third Quarter 2022 Results DENVER, November 1, 2022 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights ?Total revenue for the third quarter 2022 was approximately $26.5 million, primarily from four revenue units, compared to approximately $19.2 million, primari |
|
| September 7, 2022 |
Exhibit 99.1 ViewRay Announces China NMPA Approval of its MRIdian? MRI-Guided Radiation Therapy for Cancer Patients This approval expands MRIdian?s global reach and offers cancer patients a new radiation therapy option?MRIdian SMART DENVER, CO, September 7, 2022?ViewRay, Inc. (NASDAQ: VRAY) today announced that the company?s MRIdian MRI-Guided Radiation Therapy System has received approval from th |
|
| September 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2022 |
Exhibit 99.1 ViewRay Selects Denver for Headquarters Innovative cancer therapy company to leverage Colorado bioscience talent resources DENVER, August 08, 2022 - ViewRay, Inc. (Nasdaq: VRAY), a medical device company that designs, manufactures, and markets the MRIdian? radiation therapy system, announced today that it is moving its headquarters to Denver, Colorado as it continues to attract top-ti |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 2, 2022 |
Earnings Call – Q2 2022 August 2, 2022 Exhibit 99.2 2©2022 ViewRay Technologies, Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements in |
|
| August 2, 2022 |
ViewRay Announces Second Quarter 2022 Results Exhibit 99.1 ViewRay Announces Second Quarter 2022 Results CLEVELAND, August 2, 2022 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights •Total revenue for the second quarter 2022 was approximately $22.1 million, primarily from three revenue units and one upgrade, compared to approximately $15.0 |
|
| August 2, 2022 |
Exhibit 99.3 ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy Multiyear campaign will highlight clinical evidence and patient impact of MRIdian® for cancer treatment CLEVELAND, OH, August 2, 2022— ViewRay, Inc, the U.S. maker of the MRIdian® System, today announced a partnership with award-winning journalist and cancer advocate Katie Couric’s mu |
|
| June 14, 2022 |
As filed with the Securities and Exchange Commission on June 14, 2022 Registration No. |
|
| June 14, 2022 |
Exhibit 99.2 VIEWRAY, INC. AMENDED & RESTATED 2015 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the ViewRay, Inc. Amended & Restated 2015 Equity Incentive Award Plan (as it may be amended from time to time, the ?Plan?) is to promote the success and enhance the value of ViewRay, Inc., a Delaware corporation, (the ?Company?) by linking the individual interests of the members of the |
|
| June 14, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) VIEWRAY, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule (2) Amount Registered Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 1, 2022 |
Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 31st day of May, 2022, by and among (i) Silicon Valley Bank (?Bank?), (ii) VIEWRAY, INC., a Delaware corporation (?ViewRay?), and (iii) VIEWRAY TECHNOLOGIES, INC., a Delaware corporation (?Technologies?, and together with Viewray, individually an |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ViewRay, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-37725 42-1777485 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2 Thermo Fisher Way Oakwood Village, OH 44146 (Address of princip |
|
| May 27, 2022 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form Exhibit 1.01 VIEWRAY, INC. CONFLICT MINERALS REPORT FOR THE YEAR ENDED DECEMBER 31, 2021 This Conflict Minerals Report (?CMR?) for the year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission, (the ?SEC?), to implement reporting and disclosure requirements related to C |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| May 6, 2022 |
Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. |
|
| May 5, 2022 |
EX-99.2 3 vray-20220505exhibit992.htm EX-99.2 Earnings Call – Q1 2022 May 5, 2022 Exhibit 99.2 2©2022 ViewRay Technologies, Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-looking sta |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
ViewRay Announces First Quarter 2022 Results Exhibit 99.1 ViewRay Announces First Quarter 2022 Results CLEVELAND, May 5, 2022 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights ?Total revenue for the first quarter 2022 was approximately $18.9 million, primarily from three revenue units, compared to approximately $15.5 million, primarily fr |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
DEFA14A 1 defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| April 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 9, 2022 |
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital Exhibit 99.1 ViewRay Enters into Cooperation Agreement with Hudson Executive Capital CLEVELAND, March 9, 2022-ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP (?HEC?) to appoint Susan Schnabel to the ViewRay Board of Directors (the ?Board?) as an independent director, effective as of March 8, 2022. Ms. Schnabel brings significant financ |
|
| March 9, 2022 |
Exhibit 3 COOPERATION AGREEMENT March 8, 2022 Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, New York 10281 Ladies and Gentlemen: ViewRay, Inc. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92672L107 (CUSIP Nu |
|
| March 9, 2022 |
EX-10.1 2 vray-20220308exhibit101.htm EX-10.1 Exhibit 10.1 COOPERATION AGREEMENT March 8, 2022 Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, New York 10281 Ladies and Gentlemen: ViewRay, Inc. (the “Company”) and Hudson Executive Capital LP, on behalf of itself, its affiliates and its affiliated funds (such affiliates and affiliated funds (which, for |
|
| March 9, 2022 |
VRAY / Viewray Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 VRAYSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 VIEWRAY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92672L107 (CUSIP Number) MARCH 2, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu |
|
| February 25, 2022 |
Exhibit 21 Subsidiaries Entity Jurisdiction of Organization ViewRay Technologies, Inc. (formerly known as ViewRay Incorporated) Delaware ViewRay GmbH Germany |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-377 |
|
| February 24, 2022 |
Earnings Call ? Q4 2021 February 24, 2022 Exhibit 99.2 2?2022 ViewRay Technologies, Inc. All rights reserved. This presentation has been prepared solely for use at this call and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to ?ViewRay,? ?the compa |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 24, 2022 |
ViewRay Announces Fourth Quarter and Full Year 2021 Results EX-99.1 2 vray-20220224exhibit991.htm EX-99.1 Exhibit 99.1 ViewRay Announces Fourth Quarter and Full Year 2021 Results CLEVELAND, February 24, 2022 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021. Full Year 2021 Highlights •Total revenue of $70.1 million primarily from ten revenue units, compared t |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 13, 2022 |
J.P. Morgan Healthcare Conference January 2022 Exhibit 99.1 2?2022 ViewRay Technologies, Inc. All rights reserved. This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to ?ViewRay,? ?t |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2022 |
ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results Exhibit 99.1 ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results CLEVELAND, January 10, 2022 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2021 Prelimina |
|
| December 15, 2021 |
EX-99.1 2 vray-20211215exhibit991.htm EX-99.1 Exhibit 99.1 ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features MRIdian A3i and Brain Treatment Package Enhance On-Table Adaptive Workflow and Expand Clinical Utility CLEVELAND, December 15, 2021—ViewRay, Inc. (NASDAQ: VRAY) today announced that the company received FDA 510(k) clearance for its next ge |
|
| December 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 19, 2021 |
Exhibit 1.1 12,500,000 Shares1 ViewRay, Inc. Common Stock (Par Value $0.01 Per Share) UNDERWRITING AGREEMENT November 16, 2021 PIPER SANDLER & CO. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Stifel, Nicolaus & Company, Incorporated On |
|
| November 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 18, 2021 |
424B2 1 d229109d424b2.htm 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-261111 PROSPECTUS SUPPLEMENT (To Prospectus dated November 16, 2021) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “VRAY.” The last reported closing price of our common stock on Novemb |
|
| November 16, 2021 |
As filed with the Securities and Exchange Commission on November 16, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 16, 2021 Registration No. |
|
| November 16, 2021 |
SUBJECT TO COMPLETION, DATED NOVEMBER 16, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261111 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where |
|
| November 10, 2021 |
VRAY / Viewray Inc / Fosun International Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) November 8, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| November 5, 2021 |
Amended and restated 2015 Equity Incentive Award Plan Performance Share Award Grant Notice. Exhibit 10.1 VIEWRAY, INC. AMENDED & RESTATED 2015 EQUITY INCENTIVE AWARD PLAN PERFORMANCE SHARE AWARD GRANT NOTICE ViewRay, Inc., a Delaware corporation, (the ?Company?), pursuant to its Amended & Restated 2015 Equity Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of Performance Share Units (the ?PSUs?), whic |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 4, 2021 |
ViewRay Reports Third Quarter 2021 Results Exhibit 99.1 ViewRay Reports Third Quarter 2021 Results CLEVELAND, November 4, 2021 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights ?Received seven new orders for MRIdian systems totaling $39.4 million, compared to four new orders totaling $23.4 million in the third quarter of 2020. Total |
|
| November 4, 2021 |
Earnings Call ? Q3 2021 November 4, 2021 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 1, 2021 |
EX-10.1 2 exhibit101svbthirdamendment.htm EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 29th day of October, 2021, by and among (i) Silicon Valley Bank (“Bank”), (ii) VIEWRAY, INC., a Delaware corporation (“ViewRay”), and (iii) VIEWRAY TECHNOLOGIES, INC., a Delaware corporation (“Techn |
|
| October 28, 2021 |
Exhibit 99.1 New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting Findings Show Median Overall Survival Of 26 Months for Patients Receiving Ablative Doses with MRIdian MRI-Guided Radiation Therapy CHICAGO, October 28, 2021?ViewRay, Inc. (NASDAQ: VRAY) today announced that the results of a multi-center study of |
|
| October 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 29, 2021 |
Exhibit 99.1 ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations New suite of workflow and clinical features to be highlighted at upcoming ASTRO 2021 conference CLEVELAND, OH, September 29, 2021?ViewRay, Inc. (NASDAQ: VRAY) today announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhanci |
|
| September 10, 2021 |
EX-99.1 2 vray-ex9919.htm EX-99.1 www.viewray.com Clinical Value and Roadmap September 10, 2021 Exhibit 99.1 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the com |
|
| September 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| August 5, 2021 |
ViewRay Reports Second Quarter 2021 Results Exhibit 99.1 ViewRay Reports Second Quarter 2021 Results CLEVELAND, August 5, 2021 ? ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights ? Received seven new orders for MRIdian systems totaling $37.9 million, compared to four new orders totaling $24.6 million in the second quarter of 2020. ? Total |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 5, 2021 |
Our mission: Treat and prove what others can’t. ©2021 ViewRay, Inc. All rights reserved. Earnings Call ? Q2 2021 August 5, 2021 Exhibit 99.2 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to ?ViewRay,? ?the company,? ?we,? ?us? and ?our,? refer to ViewRay, Inc. Excep |
|
| June 24, 2021 |
Exhibit 99.1 GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian? Systems Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, Ohio, June 24, 2021?ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian? MR-Guided Th |
|
| June 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 11, 2021 |
ViewRay Announces Election of Karen N. Prange to its Board of Directors Exhibit 99.1 ViewRay Announces Election of Karen N. Prange to its Board of Directors CLEVELAND, June 11, 2021 ? ViewRay, Inc. (Nasdaq: VRAY) announced the election of Karen N. Prange to its Board of Directors by ViewRay?s stockholders at its 2021 Annual Meeting, effective today. Ms. Prange is a veteran healthcare executive and strategist with over 25 years of leadership experience. Ms. Prange has |
|
| June 11, 2021 |
EX-3.1 2 vray-ex3150.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIEWRAY, INC. June 11, 2021 ViewRay, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows: FIRST: That by the unanimous written consent of the Board of Dire |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 11, 2021 |
Second Amended and Restated Bylaws of ViewRay, Inc. vray-ex3251.htm Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF VIEWRAY, INC. (a Delaware corporation) Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF VIEWRAY, INC. ARTICLE I -CORPORATE OFFICES 1.1REGISTERED OFFICE. The registered office of ViewRay, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “cert |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ViewRay, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-37725 42-1777485 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2 Thermo Fisher Way Oakwood Village, OH 44146 (Address of princip |
|
| May 28, 2021 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form Exhibit 1.01 VIEWRAY, INC. CONFLICT MINERALS REPORT FOR THE YEAR ENDED DECEMBER 31, 2020 This Conflict Minerals Report (“CMR”) for the year ended December 31, 2020 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, (the “Rule”). The Rule was adopted by the Securities and Exchange Commission, (the “SEC”), to implement reporting and disclosure requirements related to C |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| May 6, 2021 |
ViewRay Reports First Quarter 2021 Results EX-99.1 2 vray-ex99126.htm EX-99.1 Exhibit 99.1 ViewRay Reports First Quarter 2021 Results CLEVELAND, May 6, 2021 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights • Received seven new orders for MRIdian systems totaling $40.9 million, compared to four new orders totaling $22.6 million in the f |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 6, 2021 |
Our mission: Treat and prove what others can’t. ©2021 ViewRay, Inc. All rights reserved. www.viewray.com Earnings Call - Q1 2021 May 6, 2021 Exhibit 99.2 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to ?ViewRay,? ?the company,? ?we,? ?us? and ?our,? refer to ViewRa |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2021 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 15, 2021 |
ViewRay Announces Departure of Chief Operating Officer Exhibit 99.1 ViewRay Announces Departure of Chief Operating Officer CLEVELAND, March 15, 2021 — ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021. Matin was named Chief Executive Officer designate of Cordis in its recently announced divestiture from Cardinal Health to private equity firm Hellma |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37725 ViewRay, Inc. ( |
|
| March 5, 2021 |
EX-21 2 vray-ex218.htm EX-21 Exhibit 21 Subsidiaries Entity Jurisdiction of Organization ViewRay Technologies, Inc. (formerly known as ViewRay Incorporated) Delaware ViewRay GmbH Germany |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 4, 2021 |
ViewRay Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 ViewRay Reports Fourth Quarter and Full Year 2020 Results CLEVELAND, March 4, 2021 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and year ended December 31, 2020. Full Year 2020 Highlights • Total revenue of $57.0 million primarily from nine revenue units, including two system upgrades, compared to 2019 revenue of approximately |
|
| March 4, 2021 |
EX-99.2 3 vray-ex992178.htm EX-99.2 Q4 2020 Earnings Conference Call March 4, 2021 ©2021 ViewRay, Inc. All rights reserved. Exhibit 99.2 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, refer |
|
| February 17, 2021 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex-1.htm Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the common stock, par value $0.01, of ViewRay, Inc., beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The par |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934(Amendment No. |
|
| February 12, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 12, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of issuer) Common Stock (Title of class of securities) Common Stock: 92672L107 (CUSIP number) January 21, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2021 |
ViewRay Announces Appointment of Phil Spencer to its Board of Directors EX-99.1 2 vray-ex99116.htm EX-99.1 Exhibit 99.1 ViewRay Announces Appointment of Phil Spencer to its Board of Directors CLEVELAND, February 11, 2021 — ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021. Mr. Spencer has a long track record of delivering substantial financial value as a CEO and board member over the last 20 ye |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) January 19, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 19, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) SZE Mei Ming Fosun International Limited Room 808, ICBC Tower 3 Garden Road, Central Hong Kong (852) 2509 3228 With a copy to: Gregory Wa |
|
| January 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 7, 2021 |
Exhibit 1.1 10,310,000 Shares1 Viewray, Inc. Common Stock (Par Value $0.01 Per Share) UNDERWRITING AGREEMENT January 4, 2021 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: ViewRay, Inc., a Delaware corporation (the “Company”), proposes to is |
|
| January 6, 2021 |
Sole Book-Running Manager Piper Sandler 424B2 1 d91307d424b2.htm 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-229145 PROSPECTUS SUPPLEMENT (To Prospectus dated February 7, 2019) 10,310,000 Shares Common Stock We are offering 10,310,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “VRAY.” The last reported closing price of our common stock on January |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 4, 2021 |
ViewRay Announces Preliminary Fourth Quarter and Full Year 2020 Results EX-99.1 2 vray-ex99194.htm EX-99.1 Exhibit 99.1 ViewRay Announces Preliminary Fourth Quarter and Full Year 2020 Results CLEVELAND, Ohio, January 4, 2021—ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 20 |
|
| January 4, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 4, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229145 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 5, 2020 |
Exhibit 10.1 SECOND Amendment to Loan and security agreement This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 30th day of October, 2020, by and among (i) Silicon Valley Bank (“Bank”), (ii) VIEWRAY, INC., a Delaware corporation (“ViewRay”), and (iii) VIEWRAY TECHNOLOGIES, INC., a Delaware corporation (“Technologies”, and together with Viewray, individuall |
|
| November 5, 2020 |
ViewRay Reports Third Quarter 2020 Results EX-99.1 3 vray-ex9916.htm EX-99.1 Exhibit 99.1 ViewRay Reports Third Quarter 2020 Results CLEVELAND, November 5, 2020 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights: • Total revenue of $10.1 million, primarily from one revenue unit, compared to $20.9 million, primarily from three revenue |
|
| November 5, 2020 |
Q3 2020 Earnings Conference Call November 5, 2020 ©2020 ViewRay, Inc. All rights reserved. Exhibit 99.2 This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company, |
|
| October 7, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 7, 2020 |
Exhibit 10.1 Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Version THIS AGREEMENT (this “Agreement”) is made as of October 1, 2020, by and among ViewRay Technologies, Inc., a Delaware corporation (“ViewRay”), ViewRay, Inc., a Delaware corporat |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| July 31, 2020 |
Separation Agreement, dated July 28, 2020, by and between ViewRay Inc. and Shahriar Matin. Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT This Confidential Separation Agreement (“Agreement”), dated as of July 6, 2020, is entered into between ViewRay, Inc., a Delaware Corporation, together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and Shahriar Matin (“Executive”) and hereby modifies the severance and other related provisions of that certain Employme |
|
| July 31, 2020 |
Q2 2020 Earnings Conference Call July 30, 2020 ©2020 ViewRay, Inc. All rights reserved. Exhibit 99.2 FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to |
|
| July 31, 2020 |
Separation Agreement, dated June 1, 2020, by and between ViewRay Inc. and Richard “Brian” Knaley. Exhibit 10.3 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (“Agreement”), dated as of June 1, 2020, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and Brian Knaley (“Employee”) (collectively, the “Parties”). The Parties agree |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 31, 2020 |
ViewRay Reports Second Quarter 2020 Results Exhibit 99.1 ViewRay Reports Second Quarter 2020 Results CLEVELAND, July 30, 2020 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020. Second Quarter 2020 Highlights: • Total revenue of $14.2 million, primarily from two revenue units, compared to $30.2 million, primarily from five revenue units, in the second quarter of 2019. • Received four |
|
| July 20, 2020 |
VRAY / ViewRay, Inc. / Fosun International Ltd - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) SZE Mei Ming Fosun International Limited Room 808, ICBC Tower 3 Garden Road, Central Hong Kong (852) 2509 3228 With a copy to: Gregory Wa |
|
| June 26, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 26, 2020 Registration No. |
|
| June 26, 2020 |
ViewRay, Inc. Amended and Restated 2015 Equity Incentive Award Plan. EX-99.1 Exhibit 99.1 VIEWRAY, INC. AMENDED & RESTATED 2015 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the ViewRay, Inc. Amended & Restated 2015 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of ViewRay, Inc., a Delaware corporation, (the “Company”) by linking the individual interests of the members |
|
| June 12, 2020 |
8-K 1 vray-8k20200612.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorpor |
|
| May 29, 2020 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form EX-1.01 2 vray-ex1016.htm EX-1.01 Exhibit 1.01 VIEWRAY, INC. CONFLICT MINERALS REPORT FOR THE YEAR ENDED DECEMBER 31, 2019 This Conflict Minerals Report (“CMR”) for the year ended December 31, 2019 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, (the “Rule”). The Rule was adopted by the Securities and Exchange Commission, (the “SEC”), to implement reporting and di |
|
| May 29, 2020 |
SD 1 vray-sd.htm SDFY2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ViewRay, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-37725 42-1777485 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2 Thermo Fisher Way Oakwood Village, OH |
|
| May 1, 2020 |
Severance Agreement, dated January 22, 2020, by and between ViewRay Inc. and Richard “Brian” Knaley Exhibit 10.3 CONFIDENTIAL SEVERANCE AGREEMENT This Confidential Severance Agreement (“Agreement”), dated as of January 22, 2020, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and Richard “Brian” Knaley (“Employee”) (collectively, the “Parties”). Unless otherwise defined herein, any capitaliz |
|
| May 1, 2020 |
Quarterly Report - VRAY-10Q Q1 20200331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37725 ViewRay, Inc. |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 30, 2020 |
ViewRay Names Zach Stassen as Chief Financial Officer Exhibit 99.2 ViewRay Names Zach Stassen as Chief Financial Officer CLEVELAND, April 30, 2020 – ViewRay, Inc. (Nasdaq: VRAY) announced today that Zach Stassen has been named Chief Financial Officer, effective May 18, 2020. Mr. Stassen will report directly to Scott Drake, President and Chief Executive Officer. Mr. Stassen has over 20 years of experience in the medical device and healthcare industry. |
|
| April 30, 2020 |
ViewRay Reports First Quarter 2020 Results Exhibit 99.1 ViewRay Reports First Quarter 2020 Results CLEVELAND, April 30, 2020 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2020. First Quarter 2020 Highlights: • Total revenue of $14.3 million, primarily from three revenue units including one system upgrade, compared to $20.3 million, primarily from four revenue units including one syst |
|
| April 30, 2020 |
Offer Letter to Zachary Stassen dated April 20, 2020. Exhibit 10.1 April 20th, 2020 Zachary W. Stassen Dear Zachary, Congratulations! We are excited to extend you an offer of employment with ViewRay Technologies, Inc. The details of your offer are as follows: Position: Chief Financial Officer. Reporting to Scott Drake. This is a regular, full-time position. Location: 1595 Wynkoop St., Suite 900 Denver, CO 80202 Start Date: May 18th, 2020 Compensation |
|
| April 24, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d900227ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| April 24, 2020 |
DEF 14A 1 d900200ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, |
|
| April 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 16, 2020 |
ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors Exhibit 99.1 ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors CLEVELAND, April 16, 2020 — ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020. Ms. Johnson brings a wealth of health care and medical technology knowledge, as well as broad experience in finance and corporate governance. She is c |
|
| April 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 12, 2020 |
Exhibit 10.51 Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Distribution Agreement THIS DISTRIBUTION AGREEMENT (“Agreement”) is made this 29th day of November, 2019 (the “Signing Date”) by and between ViewRay Technologies, Inc., a Delaware |
|
| March 12, 2020 |
Exhibit 10.11(i) Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Amendment Nr. 8 to the Development and Supply Agreement between ViewRay Incorporated and Siemens Aktiengesellschaft, Healthcare Sector dated 17th June 2008 by and between ViewRa |
|
| March 12, 2020 |
VRAY / ViewRay, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37725 ViewRay, Inc. ( |
|
| March 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 12, 2020 |
Exhibit 4.5 VIEWRAY, INC. DESCRIPTION OF SECURITIES DESCRIPTION OF COMMON STOCK The common stock of ViewRay, Inc. is listed on the Nasdaq Global Select Market under the symbol “VRAY.” All outstanding shares of common stock are validly issued, fully paid, and nonassessable. The following description of the terms of our common stock is not complete and is qualified in its entirety by reference to ou |
|
| March 12, 2020 |
ViewRay Reports Fourth Quarter and Full Year 2019 Results Exhibit 99.1 ViewRay Reports Fourth Quarter and Full Year 2019 Results CLEVELAND, March 12, 2020 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2019. A supplemental presentation for today's conference call is included on the Company's website at http://investors.viewray.com/events/event-details/q4-2019-viewray-inc-earnings-c |
|
| March 12, 2020 |
Separation Agreement, dated January 14, 2020, by and between ViewRay Inc. and James M. Alecxih. Exhibit 10.42 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release ("Agreement"), dated as of January 7, 2020, is entered into between ViewRay, Inc., a Delaware Corporation., together with its existing and future subsidiaries and controlled affiliates (“ViewRay"), and James "Jim" Alecxih ("Employee”) (collectively, the "Parties"). The Par |
|
| March 12, 2020 |
EX-21 8 vray-ex216.htm EX-21 Exhibit 21 Subsidiaries Entity Jurisdiction of Organization ViewRay Technologies, Inc. (formerly known as ViewRay Incorporated) Delaware ViewRay GmbH Germany |
|
| March 12, 2020 |
Exhibit 10.11(h) Contract Amendment No. 7 to the Development and Supply Agreement by and between ViewRay Incorporated with its registered seat in Oakwood Village, OH, USA -hereinafter referred to as "ViewRay"- and Siemens Healthcare GmbH with its registered seat in Munich -hereinafter referred to as "Siemens"- -ViewRay and Siemens hereinafter referred to individually as "Party" or collectively as |
|
| March 12, 2020 |
ViewRay, Inc. 2015 Employee Stock Purchase Plan, as amended February 27, 2020. Exhibit 10.26(b) VIEWRAY, INC. AMENDED AND RESTATED 2015 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1Purpose and Scope. The purpose of the Amended and Restated ViewRay, Inc. 2015 Employee Stock Purchase Plan, as it may be amended from time to time, (the “Plan”) is to assist employees of ViewRay, Inc., a Delaware corporation, (the “Company”) and its Desig |
|
| March 12, 2020 |
Q4 2019 Earnings Conference Call March 12, 2020 ©2020 ViewRay, Inc. All rights reserved. Q4 2019 Earnings Conference Call March 12, 2020 ©2020 ViewRay, Inc. All rights reserved. FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “ |
|
| February 24, 2020 |
EX-1 EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13D and any future amendments thereto reporting each of the undersigned’s ownership of securities of the Company named herein, and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. |
|
| February 24, 2020 |
Schedule of Transactions in Shares EX-2 EXHIBIT 2 Schedule of Transactions in Shares The following table sets forth all transactions with respect to Shares effected in the last sixty days by the Reporting Persons or on behalf of the Reporting Persons in respect of the Shares, inclusive of any transactions effected through 4:00 pm, New York City time, on February 24, 2020. |
|
| February 24, 2020 |
VRAY / ViewRay, Inc. / Hudson Executive Capital LP - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ViewRay, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92672L107 (CUSIP Number) Michael D. Pinnisi Hudson Executive Capital LP 570 Lexington Avenue, 35th Floor New York, NY 10022 (212) 521-8495 with a copy to: Richard M. Br |
|
| February 14, 2020 |
VRAY / ViewRay, Inc. / Park West Asset Management LLC - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 – Exit Filing)* VIEWRAY, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92672L107 (CUSIP Number) DECEMBER 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2020 |
VRAY / ViewRay, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92672L 107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2020 |
VRAY / ViewRay, Inc. / Puissance Capital Management LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ViewRay, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 950 Third Avenue, 25th Floor New York, New York 10022 Telephone Number: |
|
| February 14, 2020 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1 (k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1 (k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 14, 2020 |
VRAY / ViewRay, Inc. / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934(Amendment No. |
|
| February 14, 2020 |
VRAY / ViewRay, Inc. / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of |
|
| February 14, 2020 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the common stock, par value $0. |
|
| January 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 13, 2020 |
ViewRay Announces Preliminary Fourth Quarter and Full Year 2019 Results Exhibit 99.1 ViewRay Announces Preliminary Fourth Quarter and Full Year 2019 Results CLEVELAND, Ohio, January 13, 2020—ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2019. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2019 Preliminary Results: • Total re |
|
| January 13, 2020 |
January 2020 Exhibit 99.2 FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “we,” “us” and “our,” refer to ViewRay, Inc. Exce |
|
| December 31, 2019 |
Exhibit 10.1 FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 31st day of December, 2019, by and among (i) Silicon Valley Bank (“Bank”), (ii) VIEWRAY, INC., a Delaware corporation (“Viewray”), and (iii) VIEWRAY TECHNOLOGIES, INC., a Delaware corporation (“Technologies”, and together with Viewray, individually |
|
| December 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 12, 2019 |
VRAY / ViewRay, Inc. / Elekta AB (publ) - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ViewRay, Inc. (Name of issuer) Common Stock (Title of class of securities) Common Stock: 92672L107 (CUSIP number) December 6, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| December 10, 2019 |
VRAY / ViewRay, Inc. / Fosun International Ltd - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) SZE Mei Ming Fosun International Limited Room 808, ICBC Tower 3 Garden Road, Central Hong Kong (852) 2509 3228 With a copy to: Gregory Wa |
|
| December 10, 2019 |
Exhibit 99.5 Execution Version EQUITY COMMITMENT AGREEMENT THIS EQUITY COMMITMENT AGREEMENT (the “Agreement ”) is dated as of November 30, 2019 (the “Effective Date”), by and among ViewRay, Inc., a Delaware corporation (the “Company”), and Strong Influence Limited, a British Virgin Islands corporation (the “Investor”). RECITALS WHEREAS, the Company has filed a registration statement on Form S-3 (N |
|
| December 6, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d837922d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incor |
|
| December 6, 2019 |
EX-1.1 2 d837922dex11.htm EX-1.1 Exhibit 1.1 41,550,000 Shares1 Viewray, Inc. Common Stock (Par Value $0.01 Per Share) UNDERWRITING AGREEMENT December 3, 2019 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: ViewRay, Inc., a Delaware corporati |
|
| December 5, 2019 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229145 PROSPECTUS SUPPLEMENT (To Prospectus dated February 7, 2019) 41,550,000 Shares Common Stock ViewRay, Inc. is offering 41,550,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “VRAY.” The last reported closing price of our common stock on November 29, 2019, was |
|
| December 2, 2019 |
SUBJECT TO COMPLETION, DATED DECEMBER 2, 2019 424B5 1 d784938d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229145 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these secur |
|
| November 20, 2019 |
8-K/A 1 vray-8ka20191024.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Ot |
|
| November 19, 2019 |
VRAY / ViewRay, Inc. / Fosun International Ltd - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ViewRay, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 92672L107 (CUSIP Number) SZE Mei Ming Fosun International Limited Room 808, ICBC Tower 3 Garden Road, Central Hong Kong (852) 2509 3228 With a copy to: Gregory Wang |
|
| November 12, 2019 |
Separation Agreement, dated September 30, 2019, by and between ViewRay Inc. and Ajay Bansal. Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (the “Agreement”), dated as of September 30, 2019, is entered into between ViewRay, Inc., a Delaware Corporation, together with its existing and future subsidiaries and controlled affiliates (“ViewRay”), and Ajay Bansal (“Employee”) (collectively, the “Parties”). The Partie |
|
| November 12, 2019 |
10-Q 1 vray-10q20190930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 12, 2019 |
ViewRay Reports Third Quarter 2019 Results Exhibit 99.1 ViewRay Reports Third Quarter 2019 Results CLEVELAND, November 12, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Summary: • Total revenue was $20.9 million in the quarter, primarily from three revenue units, compared to $17.7 million, primarily from three revenue units, for the same period last |
|
| October 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 18, 2019 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the common stock, par value $0. |
|
| October 18, 2019 |
VRAY / ViewRay, Inc. / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 * ViewRay, Inc. |
|
| October 15, 2019 |
ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call Exhibit 99.1 ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call CLEVELAND, Ohio, October 15, 2019—ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change. Selected Third Quarter Preliminary Results: • Total revenue of $20.9 million in the third |
|
| October 15, 2019 |
8-K 1 vray-8k20191015.htm VRAYQ319PRELIMEARNINGSRELEASE0919 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State |
|
| October 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 ViewRay, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37725 42-1777485 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 13, 2019 |
VRAY / ViewRay, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 11 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* VIEWRAY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92672L107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephon |
|
| August 13, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 13, 2019 (the “Schedule 13D”), with respect to the Common Stock, of ViewRay, Inc. |
|
| August 12, 2019 |
VRAY / ViewRay, Inc. / HealthCor Management, L.P. - SC 13G Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) August 1, 2019 (Date of Event Which Requires Filing of this |
|
| August 12, 2019 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
